Literature DB >> 26314855

Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Jie Luo1, Bin Chen, Xian-Xiu Ji, Song-Wen Zhou, Di Zheng.   

Abstract

Nonsmall cell lung cancer (NSCLC) is a commonly occurring lung cancer. A combination of molecular biological treatments with regular chemotherapy may result in improved therapeutic outcome. Here, we reported significantly higher levels of fibroblast growth factor receptor 3 (FGFR3) and significantly lower levels of miR-100 in the NSCLC specimen, compared to the paired NSCLC-adjacent normal lung tissues. Moreover, the levels of FGFR3 and miR-100 were inversely correlated. Bioinformatics analyses followed by luciferase reporter assay showed that miR-100 bound to the 3'-UTR of FGFR3 messenger RNA (mRNA) to inhibit its translation. Overexpression of miR-100 in NSCLC cells decreased FGFR3 protein levels, whereas inhibition of miR-100 increased FGFR3 protein levels, without affecting FGFR3 mRNA levels. Furthermore, overexpression of miR-100 suppressed cancer growth, migration, and chemosensitivity in NSCLC cells, while inhibition of miR-100 significantly facilitated them. Taken together, our data demonstrate that miR-100 may inhibit NSCLC through FGFR3.

Entities:  

Year:  2015        PMID: 26314855     DOI: 10.1007/s13277-015-3850-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  42 in total

1.  Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

Authors:  Shadan Ali; Aamir Ahmad; Sanjeev Banerjee; Subhash Padhye; Kristin Dominiak; Jacqueline M Schaffert; Zhiwei Wang; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

2.  Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1.

Authors:  Prabakaran Soundararajan; James P Fawcett; Victor F Rafuse
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

3.  Characterization and functions of vascular adventitial fibroblast subpopulations.

Authors:  Sheng Jun An; Pei Liu; Tie Mei Shao; Zhi Jun Wang; Hai Gang Lu; Zhan Jiao; Xue Li; Jun Qiu Fu
Journal:  Cell Physiol Biochem       Date:  2015-02-06

4.  Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.

Authors:  Faman Xiao; Yifeng Bai; Zhenzhu Chen; Yufa Li; Luqiao Luo; Jie Huang; Jie Yang; Hongzhan Liao; Linlang Guo
Journal:  Eur J Cancer       Date:  2014-02-19       Impact factor: 9.162

5.  Targeting miR-21 for the therapy of pancreatic cancer.

Authors:  Flavie Sicard; Marion Gayral; Hubert Lulka; Louis Buscail; Pierre Cordelier
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

6.  microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3.

Authors:  Jaeku Kang; Soo Young Lee; Sun Young Lee; Young Jin Kim; Jae Yong Park; Sun Jung Kwon; Moon Jun Na; Eun Jin Lee; Hyo Sung Jeon; Ji Woong Son
Journal:  Exp Ther Med       Date:  2011-10-14       Impact factor: 2.447

7.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

8.  Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Authors:  Jakob Paur; Lisa Nika; Christiane Maier; Alexander Moscu-Gregor; Julia Kostka; Daniela Huber; Thomas Mohr; Petra Heffeter; Waltraud C Schrottmaier; Sonja Kappel; Daniela Kandioler; Klaus Holzmann; Brigitte Marian; Walter Berger; Michael Grusch; Bettina Grasl-Kraupp
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

9.  MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.

Authors:  Zhipeng Li; Xu Li; Chao Yu; Min Wang; Feng Peng; Jie Xiao; Rui Tian; Jianxin Jiang; Chengyi Sun
Journal:  Tumour Biol       Date:  2014-10-26

10.  The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells.

Authors:  Maricica Pacurari; Joseph B Addison; Naveen Bondalapati; Ying-Wooi Wan; Dajie Luo; Yong Qian; Vincent Castranova; Alexey V Ivanov; Nancy Lan Guo
Journal:  Int J Oncol       Date:  2013-05-27       Impact factor: 5.650

View more
  10 in total

1.  Inactivation of miR-100 combined with arsenic treatment enhances the malignant transformation of BEAS-2B cells via stimulating epithelial -mesenchymal transition.

Authors:  Jia Yang; Zhijun Chen; Xinyi Wang; Mo Xu; Haoshu Fang; Feifei Li; Yakun Liu; Yu Jiang; Yi Ding; Juan Li; Siying Wang
Journal:  Cancer Biol Ther       Date:  2017-11-20       Impact factor: 4.742

Review 2.  Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers.

Authors:  Zhe Dou; Shuai Lin; Cong Dai; Ye Lu; Tian Tian; Meng Wang; Xinghan Liu; Yi Zheng; Peng Xu; Shanli Li; Qianwen Sheng; Yujiao Deng; Zhijun Dai
Journal:  Oncotarget       Date:  2017-06-27

3.  Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.

Authors:  Xiaobing Qin; Shaorong Yu; Leilei Zhou; Meiqi Shi; Yong Hu; Xiaoyue Xu; Bo Shen; Siwen Liu; Dali Yan; Jifeng Feng
Journal:  Int J Nanomedicine       Date:  2017-05-15

4.  Prognostic significance of microRNA-100 in solid tumors: an updated meta-analysis.

Authors:  Jiangfeng Wang; Miao Yu; Shanghui Guan; Guangyu Zhang; Jianbo Wang; Yufeng Cheng
Journal:  Onco Targets Ther       Date:  2017-01-23       Impact factor: 4.147

5.  microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.

Authors:  Weizhong Han; Xiaoxia Ren; Yupeng Yang; Haixia Li; Lin Zhao; Zhaoxia Lin
Journal:  Thorac Cancer       Date:  2020-05-04       Impact factor: 3.500

Review 6.  MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.

Authors:  Hannah Petrek; Ai-Ming Yu
Journal:  Pharmacol Res Perspect       Date:  2019-12

7.  Roles of microRNA-99 family in human glioma.

Authors:  Mingyu Zhang; Yong Guo; Jun Wu; Fenghua Chen; Zhijie Dai; Shuangshi Fan; Pengcheng Li; Tao Song
Journal:  Onco Targets Ther       Date:  2016-06-20       Impact factor: 4.147

8.  Systematic Analysis of Transcriptomic Profile of Renal Cell Carcinoma under Long-Term Hypoxia Using Next-Generation Sequencing and Bioinformatics.

Authors:  Szu-Chia Chen; Feng-Wei Chen; Ya-Ling Hsu; Po-Lin Kuo
Journal:  Int J Mol Sci       Date:  2017-12-07       Impact factor: 5.923

9.  LncRNA NCK1-AS1 in plasma distinguishes oral ulcer from early-stage oral squamous cell carcinoma.

Authors:  Fei Le; Yangqian Ou; Ping Luo; Xiaoming Zhong
Journal:  J Biol Res (Thessalon)       Date:  2020-11-11       Impact factor: 1.889

10.  Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA.

Authors:  Qiongyu Hao; Piwen Wang; Pranabananda Dutta; Seyung Chung; Qun Li; Kun Wang; Jieqing Li; Wei Cao; Wenhong Deng; Qing Geng; Katrina Schrode; Magda Shaheen; Ke Wu; Donghui Zhu; Qiao-Hong Chen; Guanglin Chen; Yahya Elshimali; Jay Vadgama; Yong Wu
Journal:  Cell Death Dis       Date:  2020-12-11       Impact factor: 9.685

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.